INBX - NASDAQ
Inhibrx Biosciences, Inc.
$91.47
-2.3%Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
At a Glance
Live Snapshotinbx
Cash and Short Term Investments
Last Annual Value
124.22M
3-Year CAGR
-23%
5-Year CAGR
-1%
10-Year CAGR
20%
Inhibrx Biosciences, Inc. Competitors Analysis of Cash and Short Term Investments
| Company | Cash and Short Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Inhibrx Biosciences, Inc. NASDAQ:INBX | 124.22M | -23.5% | -1.1% | 20.0% | |
 Enliven Therapeutics, Inc. NASDAQ:ELVN | 462.62M | 22.3% | 33.3% | N/A | |
 Relay Therapeutics, Inc. NASDAQ:RLAY | 554.52M | -9.6% | -10.4% | N/A | |
 Atai Beckley Inc. NASDAQ:ATAI | 256.04M | 12.6% | -6.7% | N/A | |
 Amylyx Pharmaceuticals, Inc. NASDAQ:AMLX | 316.98M | -5.1% | 27.0% | N/A | |
 ORIC Pharmaceuticals, Inc. NASDAQ:ORIC | 281.49M | 10.6% | 3.5% | N/A | |
 Sana Biotechnology, Inc. NASDAQ:SANA | 138.38M | -12.3% | -24.1% | N/A | |
 Syndax Pharmaceuticals, Inc. NASDAQ:SNDX | 394.07M | -12.0% | -2.5% | 14.1% | |
 Nektar Therapeutics NASDAQ:NKTR | 245.75M | -6.8% | -19.7% | -4.5% |
Inhibrx Biosciences, Inc. Fair Value Envelope
Related Guides
Continue your INBX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.